Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin

Annals of Internal Medicine

Volumn 126, Issue 11, 1997, Pages 882-885

  Senderowicz, Adrian M ^a   Vitetta, Ellen ^b   Headlee, Donna ^a   Ghetie, Victor ^b   Uhr, Jonathan W ^b   Figg, William D ^a   Lush, Richard M ^a   Stetler Stevenson, Maryalice ^c   Kershaw, Glenn ^d   Kingma, Douglas W ^c   Jaffe, Elaine S ^c   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY CD22; PREDNISONE; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; DISEASE CLASSIFICATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

EID: 17644439829     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-11-199706010-00005     Document Type: Article

References (15)

1. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics, of post-transplant lymphoproliferative disorders. Am J Wed. 1994:97:14-24.
2. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995:46:381-94.
3. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995:85:552-65.
4. Sausville EA. Targeted toxins. In: Bertino J, ed. Encyclopedia of Cancer. San Diego: Academic Pr; 1997:1703-14.
5. Harris NL, Jaffe IS, Stein H, Banks PM, Chan JK, deary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994:84:1361-92.
6. Fisher Rl, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993:328:1002-6.
7. Sundeen J, Longo D, Jaffe E. CDS expression in B-cell small lymphocytic malignancies. Correlations with clinical presentation and sites of disease. Am J Surg Pathol. 1992; 16:130-7.
8. Kingma DW, Medeiros U, Barletta J, Raffeid M, Mann RB, Ambinder RF, et al. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease. Am J Surg Pathol. 1994;18:48-61.
9. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993; 82:1994-2004.
10. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, et al. Continuous infusion of the anti-CD22 immunotoxin IgGRFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995:85:3457-65.
11. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993:82:2624-33.
12. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al.. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994:330:1185-91.
13. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Gamier J, Niaudet P, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N EnglJ Med. 1991:324:1451-6.
14. Leblond V, Sutton L, Dorent R, Davi F, Bitker MO. Gabarre J, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol. 1995;13:961-8.
15. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Antitumor activity of Fab' and lgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 1991:51:587680.